1. A PHASE 1/2 STUDY OF MT‐3724 TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF MT‐3724 FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019) Authors: Burnett, C.A.; Hamlin, P.; Dabovic, K.; Higgins, J.; Persky, D.O. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA. (12th June 2019) Authors: Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D.J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; Hamlin, P.; Zelenetz, A.; Matasar, M.; von Keudell, G.; Sermer, D.; Yahalom, J.; Dogan, A.; Seshan, V.; Younes, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. (June 2017) Authors: Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; Kumar, A.; Matasar, M.; Moskowitz, A.; Moskowitz, C.; Noy, A.; Palomba, M.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA. (17th June 2021) Authors: Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; Hamlin, P. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. (June 2017) Authors: Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; Moskowitz, A.; Zelenetz, A.; Ahsanuddin, S.; Callan, D.; Freidin, B.; Porzio, R.; Soiffer, J.; Copeland, A.; Dang, T.; Rademaker, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. (June 2017) Authors: Soumerai, J.D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K.S.; Palomba, M.; Gerecitano, J.F.; Noy, A.; Hamlin, P.; Moskowitz, C.H.; Copeland, A.R.; Matasar, M.J.; Drullinsky, P.R.; Hamilton, A.; Horwitz, S.M.; Intlekofer, A.M.; Kumar, A.; Moskowitz, A.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗